2020 ESMO Lung Cancer Progress Large Inventory.

Wen: Ye Fenghong is affected by the new crown outbreak, and the 2020 ESMO Annual Meeting will be held in the form of an online virtual meeting.
unexpectedly, the field of lung cancer ushered in a wave of new progress, today specially organized the field of lung cancer some important research progress, in order to meet everyone.
1. FlaURA2 study early safety data published, Oghithini combined chemotherapy for first-line safety good based on FLAURA results, oxytinib has become EGFR mutation-positive late NSCLC first-line treatment preferred, FLAURA2 (NCT04035486) study aims to explore the efficacy and safety of oghithinib combination chemotherapy for first-line treatment.
early security data from the FLAURA2 study was released at the ESMO Annual Meeting.
data as of February 2020, a total of 30 patients were included in the Oghitini combined chemotherapy group: Oghitini combined with pythonse and carpone (n=15), Oghitini combined with esotonics and cisplatin (n=15).
27 patients (90%) had any adverse events, and 2 (7%) patients had their treatment interrupted due to adverse events, including 1 case of level 2 dose-limiting toxicity and 1 case unrelated to treatment, attributed to the fatal toxicity of the disease (healing).
37≥ (11/30) of class 3 adverse events occurred in the overall population.
safety data from the
FLAURA2 study show that Oghitini's combined Pyme tser and carptin/cisplatin tolerance is good, supporting further evaluation of the efficacy and safety of the program in the study.
2. ASCEND-8 Asian population study data, Seritinie 450mg with meal drug efficacy and safety was confirmed ASCEND-8 study based on the intention to treat the population data have shown that Ceritiniry 450mg with meal delivery treatment regimen tolerance effectiveness.
the ESMO Annual Meeting, ASCEND-8 Studies Asian Population Data.
data as of March 6, 2020, out of a total of 74 Asian patients included, BIRC assessed that the 450 mg on-the-food dosage group had higher ORR, medium DOR, and medium PFS than 750 mg on an empty stomach.
three-year OS rates were 93.1% and 70.9%, respectively.
the rates of gastrointestinal toxicity were 82.8%, 78.9% and 96.2% in the three groups of 450mg follow-up drug delivery group, 600mg follow-up drug delivery group and 750mg on-the-food dosage group, respectively, and 3.4%, 5.3% and 7.7%, respectively.
overall, 450 mg of follow-up drug delivery showed digitally better efficacy and lower gastrointestinal toxicity than 750 mg of prescription on an empty stomach in the Asian ALC-positive late NSCLC population.
3.MET inhibitor Capmatinib combined with third-generation EGFR-TKI Nazartinib to treat EGFR mutation NSCLC This multi-center I.b/II. phase study aims to explore the efficacy and safety of Capmatinib combined with Nazartinibl for EGFR mutation NSCLC.
study was divided into three groups, with treated patients with any T790M/MET change (group 1), untreated T79OM negative, and patients with any MET change (group 3).
data as of February 5, 2019, groups 1 and 3 included 52 and 47 patients, respectively.
ORR was 28.8% in patients in treatment group 1, ORR was 61.7% in patients in untreated group 3, ORR was 43.5% in patients with MET-positive (IHC 3 plus and/or gene copy number ≥4), and ORR was 27.9% in MET-negative patients.
safety, the frequency ≥30% of any level of treatment-related adverse events (group 1, group 3) were exo-weekly edema (50%, 57.4%), nausea (42.3%, 48.9%) and diarrhea (23.1%, 46.8%).
4. Bugatinib First Line: First-line Bugatinib vs kerotinib in Asian and non-Asian patients: ALTA-1L Update ALTA-1L (NCT02737501) Second Interim Analysis (IA2) report the latest data on the use of ALK TKI for the treatment of ALK and NSCLC in Asian and non-Asian patients.
randomly selected 275 patients, 108 Asia (BRG / CRZ, n s 59/49), 167 non-Asian (n s 78/89);
results show that the BIRC-rated BRG-medium PFS (mPFS) is 24.0 mo (95% CI 18.4-NR) in the Asian population, while CRZ mPFS is 11.1 mo (9.2-15.6) (HR 0.38 (95%CI 0.22-0.65); P - 0.0006).
among Asians, the ORR (95%CI) identified (BRG/CRZ) was 78% (65-88)/71% (57-83), P=0.3397;
asia and non-Asian regions, the duration of the BRG group iPFS is longer.
security situation for Asians and non-Asians is similar.
5. In the phase II GEOMETRY mono-1 study of the late NSCLC:GEOMETRY II study of immunotherapy METex14 mutations treated by carmatinib, Carmatini was 68% ORR in untreated METex14 NSCLC and 41% in patients treated with first/second-line treatment.
study evaluates the efficacy of carmatinini in treating immunothermed patients.
study included 69 METex14 NSCLCs.
of these cases, 19 had used IO (middle age 71; female 63.2 per cent; non-smoker 63.2 per cent) and 50 had not used IO (medium age 71.5 years; female 56 per cent; non-smoker 56 per cent).
the average tumor mutation load <10 mut / mb in both groups, 9 out of 19 patients with past IO received IO first-line treatment and 10 received IO single treatment in 10 second-line cases.
14/19 does not respond to IO.
PFS median for the previous IO was 3.29 months (95% CI 2.10-5.16).
results show that the ORR of patients treated with and without IO is: 57.9% (n s 11/19; 95% CI 33.5-79.7) and 34% (n s 17/50; 95% CI 21.2-48.8); The median DOR is 11.20 months (95% CI 3.35-NE) and 7.16 months (95% CI 4.17-11.14), respectively.
no increased risk of mesostic lung disease/pneumonia.
6. The efficacy of ntRK/ROS1-positive companion CNS transfer NSCLC was 60 years of age, 53.8% for women and 69.2% for adenocarcinoma in 13 assessable NTRK-fp NSCLC patients.
8 cases (61.5%) of CNS lesions when the baseline was used.
patients who received pre-brain radiotherapy (RT) were 5 (38.5%), of which 3 completed RT for 2 months ≥ enthinib.
of the 161 assessable ROS1-fp NSCLC patients, the medium age was 54 years, 64.6% were women and 96.9% were adenocarcinoma.
central nervous system lesions accounted for 46 cases (28.6%).
27 patients (16.8 per cent) received brain radiotherapy, 10 of whom completed ≥2 months of radiotherapy before ententini.
NTRK/ ROS1 orR was 62.5% and 52.2%, respectively, and PFS was 8.9 months and 8.3 months, respectively, in consistent with previously reported safety.
7.LAG3 single-anti-K drug first-line treatment of PDL1 insatiable metastasis non-small cell lung cancer patients preliminary results Eftilagimod alpha (efti) is a soluble LAG-3 protein, mediated antigen delivery cell (APC) activation and CD8 T cell activation.
study included patients with PDL1 insolubic NSCLC who had never been treated.
two-part, phase 1 recruited 17 patients to reach a pre-set threshold.
19 patients were recruited in Phase 2.
8 cycles of Efti injections every 2 weeks, followed by 9 cycles every 3 weeks, and the use of K medicine (200 mg infusion every 3 weeks for 2 years).
results show that all patients in Stage 1 (n s 17) are assessable.
9 patients (53%) reached PR, 5 patients (29%) had SDs, or 53% or 82% of ORR and DCR, respectively.
reactions were observed in all PD-L1 subgroups.
most common adverse events were cough (29%), fatigue (24%), decreased appetite (18%), breathing difficulties (18%), fatigue (17%), diarrhea (15%) and nausea (12%).
41% of patients are still receiving treatment and have not reached the mid-level PFS (follow-up for more than 9 months).
8. The efficacy of local late/metastasis non-scaly NSCLC in the first-line treatment of Terelliju monotherapy vs chemotherapy in this open-label Phase 3 study (NCT03663205) randomly divided Chinese patients into 2:1 ratios to receive reilly beads Anti-platinum and permeable curvature therapy, and then maintain the A arm (n-223) of the reilly pearl monoanti-Pemcosse, and the B-arm (n-111) that received the platinum-Pemcosus treatment and the maintenance treatment of the permeable curvature.
main research endpoints are PFS assessed by the Independent Review Board (PFS IRC), and secondary endpoints include ORR, DoR, and safety/tolerance.
results showed that the meso-PFS of the single anti-combination therapy of reilly was significantly longer than chemotherapy alone (9.7 months vs 7.6 months, P=0.0044; HR : 0.645, 95% CI: 0.462, 0.902).
combined chemotherapy group ORR was 57% (95% CI: 50.6, 64.0) and 37% (95% CI: 28.0, 46.0) respectively 6); The middle DoR is 8.5 months (95% CI: 6.80, 10.58) and 6.0 months (95% CI:4.99, NE), respectively.
3 levels of TRAE were ≥ 63% and 46%, respectively, in the united and chemotherapy groups.
four patients (1%) had fatal pneumonia.
three of them may be related to the single resistance of the reilly pearl.
9. Simipri monoanti-Ipimu single-anti-second-line treatment of late NSCLC Phase II randomized, open-label study 27 patients with late NSCLC were randomly assigned (1:1:1; strated by histology and PD-L1 condition), every 3 weeks (Q3W) to receive Semipri single resistance 350 mg (Arm A, n - 8); Or every 6 weeks (Q6W) Simipri monoanti-350 mg Q3W gailimu monoanti-resistance 50 mg (up to 4 doses) (arm B, n s 11) or simipri mono-resistant 1050 mg Q3W (Arm C, n s 8), the main endpoint is PD-L1 expression and lt;50% of patients with objective remission rate (ORR).
results show that the ORR (95% confidence interval) in Group A is 0% (0.0-36.9%), Group B is 45.5% (16.7-76.6%) and Group C is 11.1% (0.3-48.2%).
ORR was 36.4% (B) and 11.1% (C) for PD-L1 patients and 9.1% (B) and 0% (C) for patients with PD-L1 levels of 1-49%.
DOR has not yet been reached.
only 1 patient in Group B reported elevated levels ≥ level 3 alanine transaminase in group B.
source: 1. Planchard D, et al. Osimertinib plus platinum/pemetrexed in newly-diagnosed EGFR mutation (EGFRm)-positive advanced NSCLC: Safety run-in results from the FLAURA2 study (EB/OL). ESMO 2020, abstract 1401P.2.Cho BCC, et al. Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK plus non-small cell lung cancer (NSCLC) in the ASCEND-8 trial . ESMO 2020, abstract 1348P.3.FelipE, et al. MET resor capmatinib plus EGFR tyrosine kinase or nazartinib for EGFR-mutant-small cell lung cancer (EB/OL. ESMO 2020, abstract 1284P.4.ESMO 2020.